Development and manufacturing of functionalized oxime crosslinked hyaluronan hydrogel for sustained drug release to treat retinal degeneration

Retinal degeneration disorders are among the leading causes of blindness in the developed world. Several therapies hold promise, however widespread application is hindered due to difficulty in delivering active drug to the retina. Synakis is a company that has developed a biomaterial that can be injected into the eye to aid in retinal surgeries. This material serves as an ideal vehicle to deliver highly potent therapies to the retinal to treat retinal degeneration. This project aims to engineer Synakis’ material to deliver therapies directly to the retina. If successful, this technology will open up extensive commercial opportunities for Synakis as a platform technology to delivery critically needed regenerative therapeutics to the eye.

Faculty Supervisor:

Molly Shoichet

Student:

Partner:

Synakis

Discipline:

Life Sciences

Sector:

Manufacturing; Professional, scientific and technical services

University:

University of Toronto

Program: